February 23, 2017 07:27 AM EST
R&D

Cy­cla­cel un­veils a flop in leukemia 2 years af­ter a call on fu­til­i­ty, but still won’t give up

John Carroll

Editor & Founder

Cy­cla­cel Phar­ma­ceu­ti­cals $CY­CC knew more than two years ago that its Phase III study of sapac­itabine for new­ly di­ag­nosed cas­es of acute myeloid leukemia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times